Page 63 - Read Online

Berardi et al. J Cancer Metastasis Treat 2019;5:79 I http://dx.doi.org/10.20517/2394-4722.2019.008 Page 31 of 33

79. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med 2008;359:391-403.
80. Schafer AL, Shoback DM. Hypocalcemia: diagnosis and treatment. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A,
et al, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-2016. Available from: http://www.ncbi.nlm.nih.gov/
books/NBK279022/. [Last accessed on 26 Nov 2019]
81. Maeda SS, Fortes EM, Oliveira UM, Borba VC, Lazaretti-Castro M. Hypoparathyroidism and pseudohypoparathyroidism. Arq Bras
Endocrinol Metabol 2006;50:664-73.
82. Schäffler A. Hormone replacement after thyroid and parathyroid surgery. Dtsch Arztebl Int 2010;107:827-34.
83. Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, et al. Management of hypoparathyroidism: summary statement and
guidelines. J Clin Endocrinol Metab 2016;101:2273-83.
84. Fong J, Khan A. Hypocalcemia: updates in diagnosis and management for primary care. Can Fam Physician 2012;58:158-62.
85. Hopper AD, Hadjivassiliou M, Butt S, Sanders DS. Adult coeliac disease. BMJ 2007;335:558-62.
86. Bundred N. Antiresorptive therapies in oncology and their effects on cancer progression. Cancer Treat Rev 2012;38:776-86.
87. Sava L, Pillai S, More U, Sontakke A. Serum calcium measurement: total versus free (ionized) calcium. Indian J Clin Biochem
2005;20:158-61.
88. Shepard MM, Smith JW 3rd. Hypercalcemia. Am J Med Sci 2007;334:381-5.
89. Medas F, Erdas E, Loi G, Podda F, Pisano G, et al. Controversies in the management of parathyroid carcinoma: a case series and review
of the literature. Int J Surg 2016;28 Suppl 1:S94-8.
90. Saunders BD, Saunders EF, Gauger PG. Lithium therapy and hyperparathyroidism: an evidence-based assessment. World J Surg
2009;33:2314-23.
91. Reagan P, Pani A, Rosner MH. Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy. Am J Kidney Dis
2014;63:141-7.
92. Liou JH, Cho LC, Hsu YH. Paraneoplastic hypercalcemia with metastatic calcification - clinicopathologic studies. Kaohsiung J Med Sci
2006;22:85-8.
93. Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG, Merkel AR, et al. TGF-β promotion of Gli2-induced expression of parathyroid
hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical hedgehog signaling. Cancer Res
2011;71:822-31.
94. Stewart AF, Adler M, Byers CM, Segre GV, Broadus AE. Calcium homeostasis in immobilization: an example of resorptive
hypercalciuria. N Engl J Med 1982;306:1136-40.
95. Wesson LC, Suresh V, Parry RG. Severe hypercalcaemia mimicking acute myocardial infarction. Clin Med (Lond) 2009;9:186-7.
96. Crowley R, Gittoes N. How to approach hypercalcaemia. Clin Med (Lond) 2013;13:287-90.
97. Hagerty DR. Evidence-based treatment of hypercalcemia. Medescape 2009. Available from: https://www.medscape.com/
viewarticle/702842 [Last accessed on 26 Nov 2019]
98. Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia. Q J Med 1981;50:473-81.
99. LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med
2008;149:259-63.
100. Austin LA, Heath H 3rd. Calcitonin: physiology and pathophysiology. N Engl J Med 1981;304:269-78.
101. Dumon JC, Magritte A, Body JJ. Nasal human calcitonin for tumor-induced hypercalcemia. Calcif Tissue Int 1992;51:18-9.
102. Strumpf M, Kowalski MA, Mundy GR. Effects of glucocorticoids on osteoclast-activating factor. J Lab Clin Med 1978;92:772-8.
103. Santini D, Vespasiani Gentilucci U, Vincenzi B, Picardi A, Vasaturo F, et al. The antineoplastic role of bisphosphonates: from basic
research to clinical evidence. Ann Oncol 2003;14:1468-76.
104. Schwartz LM, Woloshin S. Lost in transmission - FDA drug information that never reaches clinicians. N Engl J Med 2009;361:1717-20.
105. Zacchia M, Abategiovanni ML, Stratigis S, Capasso G. Potassium: from physiology to clinical implications. Kidney Dis (Basel)
2016;2:72-9.
106. Eleftheriadis T, Leivaditis K, Antoniadi G, Liakopoulos V. Differential diagnosis of hyperkalemia: an update to a complex problem.
Hippokratia 2012;16:294-302.
107. Gennari FJ. Disorders of potassium homeostasis. Hypokalemia and hyperkalemia. Crit Care Clin 2002;18:273-88.
108. Clausen T, Everts ME. Regulation of the Na, K-pump in skeletal muscle. Kidney Int 1989;35:1-13.
2+
+
109. Haren N, Khorsi H, Faouzi M, Ahidouch A, Sevestre H, et al. Intermediate conductance Ca activated K channels are expressed and
functional in breast adenocarcinomas: correlation with tumour grade and metastasis status. Histol Histopathol 2010;25:1247-55.
110. Altintas DM, Allioli N, Decaussin M, de Bernard S, Ruffion A, et al. Differentially expressed androgen-regulated genes in androgen-
sensitive tissues reveal potential biomarkers of early prostate cancer. PLoS One 2013;8:e66278.
+
111. Girault A, Privé A, Trinh NT, Bardou O, Ferraro P, et al. Identification of KvLQT1 K channels as new regulators of non-small cell lung
cancer cell proliferation and migration. Int J Oncol 2014;44:838-48.
112. Crociani O, Zanieri F, Pillozzi S, Lastraioli E, Stefanini M, et al. hERG1 channels modulate integrin signaling to trigger angiogenesis and
tumor progression in colorectal cancer. Sci Rep 2013;3:3308.
113. Ding XW, Wang XG, Luo HS, Tan SY, Gao S, et al. Expression and prognostic roles of Eag1 in resected esophageal squamous cell
carcinomas. Dig Dis Sci 2008;53:2039-44.
114. Lastraioli E, Perrone G, Sette A, Fiore A, Crociani O, et al. hERG1 channels drive tumour malignancy and may serve as prognostic factor
in pancreatic ductal adenocarcinoma. Br J Cancer 2015;112:1076-87.
115. Shao XD, Wu KC, Guo XZ, Xie MJ, Zhang J, et al. Expression and significance of HERG protein in gastric cancer. Cancer Biol Ther